The position of cyproterone acetate (CPA), a steroidal anti‐androgen, in the treatment of prostate cancer

@article{Voogt1992ThePO,
  title={The position of cyproterone acetate (CPA), a steroidal anti‐androgen, in the treatment of prostate cancer},
  author={H. D. de Voogt},
  journal={The Prostate},
  year={1992},
  volume={21}
}
  • H. D. de Voogt
  • Published 1992
  • Medicine
  • The Prostate
  • Cyproterone acetate is a steroidal anti‐androgen that blocks the androgen‐receptor interaction and reduces serum testosterone through its weak anti‐gonadotropic action. It can be regarded as the only anti‐hormone that causes complete androgen blockade as monotherapy. Many animal experiments and several clinical phase II and phase III trials have demonstrated that it deserves a place in the endocrine therapy of advanced prostate cancer, particularly for those patients who find orchidectomy… CONTINUE READING
    11 Citations

    Topics from this paper.

    The future of antihormone therapy: innovations based on an established principle
    • 12
    Androgen deprivation therapy for prostate cancer
    • 14
    • Highly Influenced
    Cyproterone acetate monotherapy in advanced prostatic carcinoma
    • 1
    Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models
    • 14
    • PDF
    Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
    • 22
    • PDF
    The Current State of Hormonal Therapy for Prostate Cancer
    • 329